【24h】

Personalized nanomedicine for the treatment of vascular hypertension in polycystic kidney disease models

机译:个性化纳米药物治疗多囊肾病模型中的血管性高血压

获取原文
获取外文期刊封面目录资料

摘要

In our current study,we designed a nanomedical device for the treatment of vascular hypertension in polycystic kidney disease(PKD)model through cilia targeting.We generated and compared two different metal and polymer cilia-targeted nanoparticle drug delivery systems(DDS),i.e.gold(Au)and poly-actic-co-glycolic acid(PLGA)nanoparticles(NPs).These DDS were targeted to dopamine-receptor type-5(DR5)on primary cilia and also loaded with fenoldopam(FD).The structures and sizes of the DDS were visualized with transmission electron microscopy(TEM).The size of the DDS was also confirmed with the dynamic light scattering.The diameters of Au-NPs and PLGA-NPs were approximately 40±2.5 and 102±4.8 nm,respectively.The surface charge of Au-NPs(-47.3 ± 1.2 mV)was significantly more negative than PLGA-NPs(-25.9 ± 1.0 mV).Fourier transform infrared spectroscopy(FTIR)also confirmed the conjugation of DR5 antibody with both DDS.Our in vivo studies reveal that both DDS showed improved blood pressure in PKD mice through NO mediated vasodilation.
机译:在我们目前的研究中,我们设计了一种纳米医疗设备,通过纤毛靶向治疗多囊肾病(PKD)模型中的血管性高血压。我们制备并比较了两种不同的金属和聚合物纤毛靶向纳米颗粒药物递送系统(DDS),即金(Au)和聚乳酸-羟基乙酸(PLGA)纳米颗粒(NPs)。这些DDS靶向于初级纤毛上的多巴胺受体5型(DR5),并含有非诺多泮(FD)。用透射电子显微镜(TEM)观察DDS的结构和大小。动态光散射也证实了DDS的尺寸。Au-np和PLGA-np的直径分别约为40±2.5和102±4.8nm。Au-NPs(-47.3±1.2mv)的表面电荷明显比PLGA-NPs(-25.9±1.0mv)负。傅立叶变换红外光谱(FTIR)也证实了DR5抗体与两种DDS的结合。我们的体内研究表明,两种DDS均通过NO介导的血管舒张作用改善PKD小鼠的血压。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号